Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S.
Takeuchi S, et al. Among authors: hase t.
Cancer Sci. 2020 Feb;111(2):561-570. doi: 10.1111/cas.14260. Epub 2020 Jan 6.
Cancer Sci. 2020.
PMID: 31782583
Free PMC article.
Clinical Trial.